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Combined  hepatocellular-cholangiocarcinoma  is  a  rare  form  of  primary  liver  cancer  showing  features  of  both 
hepatocellular  and  biliary  epithelial  differentiation.  We  report  here  on  a  case  with  collision  tumor,  which  apparently  was 
the  coincidental  occurrence  of  both  hepatocellular  carcinoma  and  cholangiocarcinoma  underlying  schistosomiasis.  A 
39-year-old-Philippine  female  was  transferred  to  our  hospital  for  evaluation  of  a  liver  mass  that  was  found  on 
ultrasonography  at  a  local  hospital.  HBsAg  and  Anti-HCV  were  negative  and  serum  alpha-fetoprotein  (AFP)  level  was 
normal.  The  tumor  mass  was  histologically  diagnosed  as  adenocarcinoma  by  sono-guided  biopsy  before  the  operation. 
Partial  lobectomy  was  performed  and  we  histologically  identified  the  concurrent  occurrence  of  hepatocellular  carcinoma 
and  cholangiocarcinoma,  (a  “collision  type  carcinoma”). 
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INTRODUCTION 
More  than  80%  of  primary  liver  cancers  are  hepatocellular 
carcinomas  (HCCs),  and  these  tumors  usually  occur  in  livers 
that  are  cirrhotic  due  to  chronic  hepatitis  B  or  C  viral  infections, 
a  high  alcohol  intake  or  hemochromatosis
1).  The  second  most 
frequent  primary  tumors  of  the  liver  are  cholangiocarcinomas 
(CC);  they  account  for  about  15%  of  primary  liver  cancers,  and 
they  usually  occur  in  fibropolycystic  disease,  during  a  chronic 
inflammatory  process  of  the  bile  ducts  and  after  exposure  to 
thorotrast  or  steroids
2-5).  A  less  frequent  primary  liver  tumor  type 
is  the  hepatocellular  carcinoma-cholangiocarcinoma  (HCC-CC) 
which  shows  dual  hepatocellular  and  biliary  epithelial 
differentiations  in  the  same  tumor,  yet  these  have  rarely  been 
reported  on  in  the  English  and  Korean  literature
6).  We  report 
here  on  a  case  of  collision  tumor  in  the  liver  with  schistosome 
infection,  and  there  was  metastatic  lesion  in  the  lymph  node 
specimen. 
CASE REPORT 
A  39-year-old  Philippine  female  was  transferred  to  our 
hospital  for  evaluation  of  a  liver  mass  that  was  observed  on 
abdominal  ultrasonography  at  a  local  hospital.  She'd 
experienced  right  upper  quadrant  pain  for  the  previous  2 
months.  The  patient  had  no  history  of  diabetes,  hepatitis  or 
tuberculosis.  She  had  no  history  of  alcohol  drinking  or  smoking. 
On  admission,  the  body  temperature  was  37℃,  the  pulse  rate 
was  66  per  minute,  the  respiration  rate  was  20  per  minute  and 
the  blood  pressure  was  100/60  mmHg.  Physical  examinations 
showed  anicteric  sclerae  with  non-anemic  conjunctivae  and  no The  Korean  Journal  of  Internal  Medicine  :  Vol.  22,  No.  4,  December  2007 284
 
Figure  1. Abdominal  enhanced  CT  scan.  (A)  A  3.6×4.8 cm sized ill-defined  enhancing  mass  is  shown  in  segment  6  of  the  liver  on  the 
arterial  phase  (arrow).  (B)  Another  3.3×2.6 cm sized ill-defined  enhancing  mass  is  seen  at  the  porta  hepatis  (arrowhead)  and  a  part  of 
the  mass  at  segment  6  of  the  liver  is  seen  during  the  portal  phase  (arrow). 
Figure  2.  The  microscopic  findings  of  the  mass  in  segment  6 
show  an  adenocarcinoma  with  moderate  differentiation  by  ultra-
sonography-guided  needle  biopsy  (H&E  stain,  ×40). 
Figure  3.  Microscopic  findings.  (A)  Surgical  specimen  of  the  liver 
shows  the  histologically  identified  concurrent  occurrence  of 
hepatocellular  carcinoma  (left  upper)  and  cholangiocarcinoma  (right 
lower)  (H&E  stain,  ×40).  Several  calcified  schistosome  eggs 
(arrowheads)  with  fibrosis  are  noted  between  the  two  components. 
(B)  Hepatocellular  carcinoma  and  (C)  cholangiocarcinoma,  respec-
tively  (H&E  stain,  ×100).  (D)  The  lymph  node  biopsy  was  positive 
for  metastasis,  and  the  node  contained  hepatocellular  carcinoma 
(H&E  stain,  ×400). 
cervical  lymphadenopathy.  Abdominal  palpation  revealed  no 
palpable  mass.  Laboratory  examinations  were  performed.  The 
complete 
blood  count  was  8,300/mm
3  (neutrophils:  66.1%,  lymphocytes: 
33%,  eosinophils:  2.8%)  for  the  white  cell  count,  10.8  g/dL  for 
the  hemoglobin  level,  32.2%  hematocrit  and  256,000/mm
3  for  the 
platelets  count.  The  blood  chemistry  showed  79  mg/dL  of 
fasting  glucose,  15.4  mg/dL  of  urea  nitrogen,  1.2  mg/dL  of 
creatinine,  7.0  mg/dL  of  total  protein,  3.6  mg/dL  of  albumin,  26 
IU/L  of  AST,  35  IU/L  of  ALT,  357  IU/L  of  alkaline  phosphatase, 
0.5  mg/dL  of  total  bilirubin  and  a  normal  prothrombin  time. 
HBsAg  and  Anti-HCV  were  negative  and  anti-HBs  was  positive. 
The  tumor  marker  study  showed  that  AFP,  CEA,  CA  19-9  and 
CA  125  were  all  normal.  A  chest  radiograph  showed  no 
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Figure  4.  Gross  findings  after  partial  right  lobectomy.  Cut-section 
examination  shows  several  nodular  shaped  components  of 
hepatocellular  carcinoma  (arrowheads)  and  homogenous  sclerotic 
components  of  cholangiocarcinoma  (arrow)  with  a  whitish  central 
scar. 
sized  ill-defined  peripheral  enhancing  mass  at  segment  6  of  the 
liver  (Figure  1A)  and  another  3.3×2.6  cm  mass  of  the  same 
nature  at  the  porta  hepatis  (Figure  1B).  Ultrasonography-guided 
liver  biopsy  was  done  and  biopsy  of  the  mass  at  segment  6  of 
the  liver  disclosed  an  adenocarcinoma  with  moderate 
differentiation  (Figure  2),  and  biopsy  of  the  mass  at  the  porta 
hepatis  disclosed  a  mild  lymphocytic  infiltration.  So,  we  search 
for  the  other  primary  origin;  esophagogastrodaodenoscopy  and 
colonoscopy  were  performed  and  they  showed  nonspecific 
findings.  Breast  ultrasonography  showed  multiple  fibroadenomas 
in  both  breasts  that  were  regarded  as  benign  findings,  category 
3,  and  the  bone  scan  showed  no  evidence  of  definite  skeletal 
metastasis.  We  referred  the  patient  to  the  department  of  general 
surgery  for  surgical  intervention.  Partial  right  lobectomy  was 
performed.  The  surgical  specimen  of  the  liver  mass  disclosed 
the  concurrent  occurrence  of  hepatocellular  carcinoma  and 
cholangiocarcinoma,  which  can  be  called  a  “collision  type 
carcinoma”,  and  there  were  numerous  calcified  schistosome 
eggs  and  also  fibrosis  between  the  components  of 
hepatocellular  carcinoma  and  cholangiocarcinoma  (Figure  3,  4). 
The  lymph  node  specimen  was  positive  for  metastasis;  it 
contained  the  HCC  component.  She  was  discharged  with  an 
improved  condition.  After  one  month  from  discharge,  she  was 
readmitted  to  the  hospital  due  to  her  poor  general  condition. 
Abdominal  CT  disclosed  new  development  of  several  small 
hypodense  lesions  at  the  remaining  liver  that  suggested 
intrahepatic  metastasis  and  new  development  of  multiple 
metastatic  lymphadenopathies  along  the  celiac  trunk  and 
common  hepatic  artery,  and  there  was  about  a  1cm  sized  lung 
nodule  in  left  lower  lobe,  which  was  suspected  to  be 
hematogenous  metastasis.  The  patient  expired  due  to 
multiorgan  failure  on  the  29th  hospital  day. 
 DISCUSSION 
The  occurrence  of  combined  HCC-CC  has  been  recognized 
for  many  years,  but  the  histopathologic  features  of  these  tumors 
have  rarely  been  detailed.  Allen  and  Lisa
7)  classified  combined 
HCC-CC  into  the  following  three  categories;  1)  separate  tumors, 
each  composed  of  only  one  type  cell;  2)  contiguous  tumors, 
each  of  a  different  cell  type  that  may  mingle  as  they  grow;  and 
3)  individual  lesions  that  have  both  types  of  cells  and  are 
interpreted  to  have  arisen  from  the  same  site.  Zachary  and 
Goodman
8)  reported  24  case  of  this  tumor,  and  three  histologic 
types  were  encountered.  Four  cases  were  Type  I  or  "collision 
tumors,  and  they  were  apparently  the  coincidental  occurrence  of 
both  hepatocellular  carcinoma  and  cholangiocarcinoma  in  the 
same  patient.  Twelve  cases  were  Type  II  or  "transitional 
tumors,"  in  which  there  were  areas  of  intermediate  differentiation 
and  an  identifiable  transition  between  HCC  and  CC.  Eight  cases 
were  Type  III  or  "fibrolamellar  tumors"  that  resembled  the 
fibrolamellar  variant  of  HCC,  but  which  also  contained 
mucin-producing  pseudoglands.  In  our  case,  the  mass  was 
categorized  as  a  "collision  tumor",  which  is  the  coincidental 
occurrence  of  both  hepatocellular  carcinoma  and  cholagio-
carcinoma  with  no  transitional  area. 
Several  immunohistochemical  studies  have  focused  on  the 
differential  diagnosis  of  HCC  and  CC
9-13).  AFP  is  one  of 
markers  of  HCC,  but  immunoreactivity  for  AFP  is  focal,  if 
present  at  all
13),  and  a  significant  number  of  cases  are  AFP 
negative.  Similarly,  CEA,  which  is  a  well-known  marker  of  CC, 
is  not  always  demonstrable.  Thus,  the  usefulness  of  these 
antibodies  for  differentiation  between  HCC  and  CC  is  somewhat 
limited
8, 14).  Liver  cells  and  biliary  epithelial  cells  express 
cytokeratins  8  and  18,  and  biliary  epithelial  cells  express  7,  8,  18 
and  19
10-12).  Haratake  et  al.  tested  the  usefulness  of  two 
antibodies,  AE1  and  Cam  5.2,  and  they  reported  that  AE1  was 
the  most  useful  marker  for  differentiating  CC  from  HCC
15).  In  our 
case,  the  CC  areas  were  positive  for  cytokeratin  7  and  19,  and 
they  were  weakly  positive  for  Hepa-1  which  is  found  in  HCC. 
On  other  immnunohistochemical  studies,  Alpha-1-antitrypsin, 
IgG  and  carcinoembryonic  antigen  may  be  found  in  HCC,  CC 
and  in  combined  tumors,  and  so  these  antigens  are  of  limited 
use  in  the  differential  diagnosis
8). 
There  are  differences  in  the  clinical  features  between  the 
histologic  types  of  combined  HCC-CC.  In  particular,  Type  III 
tumors  differed  from  the  other  two  types.  The  4  patients  with 
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Type  II  tumors  occurred  in  patients  with  an  average  age  of  47 
years,  and  the  8  Type  III  tumors  occurred  in  patient  with  an 
average  age  of  30  years.  Furthermore,  five  of  the  patients  with 
Type  III  tumors  were  younger  than  30  years.  Although  three  of 
the  four  Type  I  tumors  (75%)  and  eight  of  the  ten  Type  II 
tumors  (80%)  occurred  in  cirrhotic  livers,  none  of  the  Type  III 
tumors  occurred  in  the  setting  of  cirrhosis.  Similarly,  there  was 
a  difference  in  survival  after  diagnosis.  None  of  the  patients  with 
Type  I  or  Type  II  tumors  lived  more  than  2  months  from  the 
diagnosis.  The  eight  patients  with  Type  III  tumors  had  an 
average  survival  of  14  months  after  diagnosis,  and  two  patients 
lived  longer  than  2  years
8).  The  survival  time  of  our  patient  from 
the  diagnosis  was  2  months.  In  the  report  of  the  liver  cancer 
study  group  of  Japan,  metastases  of  HCC  were  most  frequent 
in  the  lung  (45.1%),  followed  by  lymph  nodes  (34.9%),  and 
metastases  of  CC  were  most  frequent  in  the  lymph  node 
(62.5%),  followed  by  the  peritoneum  (46.3%).  Lung  metastasis  of 
combined  HCC-CC  was  the  most  frequent  (83.3%),  followed  by 
metastasis  to  the  peritoneum  (66.6%)  and  the  adrenal  glands 
(50.0%)
16).  Yet  in  our  case,  the  mass  of  the  lymph  node 
metastasis  contained  the  HCC  component. 
In  this  case,  the  etiological  relationship  of  schistosomiasis  to 
combined  HCC-CC  is  difficult  to  prove.  It  is  possible  that  the 
HCC  and  CC  each  developed  coincidentally  or  subsequently 
from  fibrosis  after  recurrent  inflammation  at  the  site  of 
schistosome  infection. 
In  conclusion,  we  report  here  on  a  rare  case  with  collision 
tumor,  which  was  apparently  the  coincidental  occurrence  of  both 
hepatocellular  carcinoma  and  cholangiocarcinoma  underlying 
schistosomiasis,  and  the  lymph  node  metastasis  contained  the 
HCC  component. 
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